YCAAD has been involved in a host of both industry and investigator sponsored trials. Below is a list of the most recent studies patients at YCAAD have been part of.
Open to enrollment
- Centocor, Inc. --- A Multicenter Longitudinal Study for the Disease Profiling of Asthma.
- NIH --- Mechanisms and Mediators of Lung Disease Open to enrollment.
- GSK --- Mepolizumab Compassionate Use Supply Program.
Active but closed to enrollment
- Genentech --- An Epidemiologic Study of Xolair (Omalizumab): Evaluating Clinical Effectiveness and Long-Term Safety in Patients with Moderate to Severe Asthma (EXCELS)
Closed to accrual
- GSK --- A multicentre, randomized, double blind, placebo-controlled, parallel group, dose ranging study to determine the effect of mepolizumab on exacerbation rates in subjects with severe uncontrolled refractory asthma (MEA 112997)